Design Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: SR One Capital's Stake in Design Therapeutics Dips
SR One Capital reports a decrease in its beneficial ownership percentage of Design Therapeutics, Inc. common stock due to an increase in the total outstanding shares.
NASDAQ
Logos Global Management LP and affiliated entities, including Arsani William, have reduced their beneficial ownership in Design Therapeutics, Inc. to 4.4% following Dr. William's resignation from the board.
NASDAQ
Logos Global Management LP and affiliated entities updated their beneficial ownership in Design Therapeutics, Inc. to 5.7% following a share sale and the resignation of Dr. Arsani William from the board.